Population-Level Interventions Cost-Effective for Reducing Risk for Dementia
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 1, 2024 -- Population-level interventions could be cost-saving and increase quality-adjusted life years (QALYs) by reducing the risk for dementia, according to a study published online July 31 in The Lancet Healthy Longevity to coincide with the Alzheimer's Association International Conference, held from July 28 to Aug. 1 in Philadelphia.
Naaheed Mukadam, Ph.D., from University College London, and colleagues estimated the cost-effectiveness of population-level interventions for addressing dementia risk factors. Population-based interventions were included from a previously published review article for which there was consistent and robust evidence of effectiveness. The interventions studied were increases in tobacco pricing, minimum pricing for alcohol, raising alcohol price, salt and sugar reduction policies, low emission zones, and compulsory helmet use for cycling by children.
The researchers estimated that minimum unit pricing leading to reductions in excess alcohol use would result in cost savings of £280 million and 4,767 quality-adjusted life years (QALYs) gained over an indefinite succession of age cohorts. Reducing salt and sugar in foods would lead to cost savings of £2.4 billion and £1.046 billion, and 39,433 and 17,985 QALYs gained, respectively. Introduction of low emission zones in English cities with a population of 100,000 or more would lead to £260 million in cost savings and 5,119 QALYs gained by reducing dementia risk from air pollution. Raising cigarette prices could lead to cost savings of £157 million and 2,277 QALYs gained. Making bicycle helmets compulsory for children could reduce dementia risk from head injury leading to £91 million in cost savings and 1,554 QALYs gained.
"Our analysis further strengthens the argument for implementation of effective population-level policies as soon as practicably possible," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-08-02 07:15
Read more
- Primary Care Encounter Notes Often Lack Thoroughness
- 2010 to 2021 Saw Rise in Postpartum Depression
- Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
- July 2019 to June 2023 Saw Increase in OD Deaths With Ketamine Detected
- What You Need to Know About FluMist, the Nasal Flu Vaccine
- Young Adults Born Preterm Face Economic and Educational Challenges
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions